CDTX vs. ORIC, VECT, TECX, KURA, HUMA, CRGX, PHVS, ANNX, KROS, and MREO
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Tectonic Therapeutic (TECX), Kura Oncology (KURA), Humacyte (HUMA), CARGO Therapeutics (CRGX), Pharvaris (PHVS), Annexon (ANNX), Keros Therapeutics (KROS), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.
Cidara Therapeutics vs.
Cidara Therapeutics (NASDAQ:CDTX) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
Cidara Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cidara Therapeutics received 384 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 73.03% of users gave ORIC Pharmaceuticals an outperform vote while only 70.27% of users gave Cidara Therapeutics an outperform vote.
ORIC Pharmaceuticals has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. ORIC Pharmaceuticals' return on equity of -42.47% beat Cidara Therapeutics' return on equity.
In the previous week, ORIC Pharmaceuticals had 14 more articles in the media than Cidara Therapeutics. MarketBeat recorded 15 mentions for ORIC Pharmaceuticals and 1 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 0.59 beat ORIC Pharmaceuticals' score of 0.17 indicating that Cidara Therapeutics is being referred to more favorably in the media.
Cidara Therapeutics presently has a consensus target price of $32.20, indicating a potential upside of 48.39%. ORIC Pharmaceuticals has a consensus target price of $18.29, indicating a potential upside of 90.87%. Given ORIC Pharmaceuticals' higher possible upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than Cidara Therapeutics.
Cidara Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 7.6% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cidara Therapeutics and ORIC Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CDTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CDTX Stock Alerts